The Cambridge-based biopharmaceutical aims for its supply chain to be carbon negative by 2030.
The Babraham Research Campus company provides an alternative to animal testing using liver, heart, brain, pancreas and immunological cells.
CRUK suggests the molecule could offer improved anti-tumor activity with fewer side effects compared to antibody-based approaches.
A rival to CMR Surgical’s Versius, the SPORT system is focused on using single incisions.
The sequencing companies were left frustrated by time taken for regulatory approval.
The Cambridge Science Park company and its sister firm will receive an upfront payment of $20million.
‘I wasn’t particularly good at school,’ he admits.
An interview with CEO Dr Heikki Lanckriet.
Several enzymes have been identified under the collaboration.
Chinese Medical Systems will offer seed investment capital in five-year programme.
He has led the robotics company from start-up to billion-dollar status and it is set to transform minimal access surgery.
The Cambridge company will use its Healnet AI platform to help identify new indications.